Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER3-DXd in Metastatic or Unresectable Non-small Cell Lung Cancer
NCT03260491Phase 1Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2017
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, randomised, open-label trial of patritumab deruxtecan in non-small cell lung cancer (NSCLC) (10 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-limiting toxicities at 21 days, Adverse Events at 36 months and 3 more. Started Oct 2017; status: active, not recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03260491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03260491.